Pharma: Bayers Xarelto-Nachfolger Asundexian in China zugelassen

Outlet: Handelsblatt · dpa-AFX · Published 26/10/2026 08:56 UTC

Only Handelsblatt reports this: no contrast yet

None of the other outlets we follow has reported this story, so there are no versions to compare. If others publish it or data appear that test it, it will move to the comparison.

Bayer erhält in China grünes Licht für neuen Schlaganfallschutz. Asundexian ist das erste dort zugelassene Medikament einer neuen Klasse von Gerinnungshemmern.

Read on the original outlet ↗

Capture record

Source: https://www.handelsblatt.com/unternehmen/industrie/pharma-bayers-xarelto-nachfolger-asundexian-in-china-zugelassen/100264912.html
Published: 26/10/2026 08:56 UTC
Captured: 26/10/2026 09:10 UTC
Text fingerprint: 355ff6a533a73cf9 · 250 words
Changes detected: 0
Archived copy: Wayback Machine ↗

The fingerprint (sha256) and the capture date prove what the story said when we analysed it, even if it changes later.